{"filing":{"accession_number":"0001232524-26-000044","cik":"0001232524","ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"jazz-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/jazz-20260803.htm"},"events":[{"id":23385,"run_id":21141,"accession_number":"0001232524-26-000044","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Jazz Pharmaceuticals issued a press release on August 3, 2026 announcing second quarter 2026 financial results, including total revenues of $1.2 billion (+16% YoY), GAAP EPS of $2.78, and raised full-year 2026 revenue guidance to $4.60-$4.75 billion. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly discloses quarterly financial results, which is the hallmark of an earnings release.","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23595,"accession_number":"0001232524-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Jazz Pharmaceuticals issued a press release on August 3, 2026 announcing second quarter 2026 financial results, including total revenues of $1.2 billion (+16% YoY), GAAP EPS of $2.78, and raised full-year 2026 revenue guidance to $4.60-$4.75 billion. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly discloses quarterly financial results, which is the hallmark of an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:24:17.803312+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23595,"accession_number":"0001232524-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Jazz Pharmaceuticals issued a press release on August 3, 2026 announcing second quarter 2026 financial results, including total revenues of $1.2 billion (+16% YoY), GAAP EPS of $2.78, and raised full-year 2026 revenue guidance to $4.60-$4.75 billion. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly discloses quarterly financial results, which is the hallmark of an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:24:17.803312+00:00","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-08-03"}]}